Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + dexamethasone induction followed by high-dose melphalan and autologous stem cell transplantation for newly diagnosed AL amyloidosis
NL-OMON23469Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Jan 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib, dexamethasone and melphalan in light-chain amyloidosis (2 arms), sponsored by HOVON. Primary endpoint: Hematologic complete response rate 6 months after autologous SCT. Started Jan 2012; status: active, not recruiting.
02
Drugs
bortezomibdexamethasonemelphalan
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NL-OMON23469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23469.